Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Capital Expenditures (2017 - 2025)

Historic Capital Expenditures for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $251000.0.

  • Sutro Biopharma's Capital Expenditures fell 6968.6% to $251000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 2569.86%. This contributed to the annual value of $3.1 million for FY2024, which is 2820.39% down from last year.
  • Sutro Biopharma's Capital Expenditures amounted to $251000.0 in Q3 2025, which was down 6968.6% from $86000.0 recorded in Q2 2025.
  • In the past 5 years, Sutro Biopharma's Capital Expenditures ranged from a high of $5.4 million in Q2 2021 and a low of $86000.0 during Q2 2025
  • For the 5-year period, Sutro Biopharma's Capital Expenditures averaged around $1.7 million, with its median value being $1.2 million (2025).
  • In the last 5 years, Sutro Biopharma's Capital Expenditures soared by 21140.24% in 2021 and then tumbled by 8862.43% in 2025.
  • Sutro Biopharma's Capital Expenditures (Quarter) stood at $2.5 million in 2021, then skyrocketed by 32.72% to $3.4 million in 2022, then plummeted by 57.2% to $1.4 million in 2023, then fell by 25.88% to $1.1 million in 2024, then plummeted by 76.5% to $251000.0 in 2025.
  • Its last three reported values are $251000.0 in Q3 2025, $86000.0 for Q2 2025, and $1.2 million during Q1 2025.